S. Cyrus Khojasteh

Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism

Ben‐Quan Shen, Daniela Bumbaca, Ola M. Saad et al. · Current Drug Metabolism · 2012 · 135 citations

Oncology, Trastuzumab Emtansine, Clinical Catabolism +13

Drug–Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug–Drug Interaction Prediction

Jane R. Kenny, Sophie Mukadam, Chenghong Zhang et al. · Pharmaceutical Research · 2012 · 94 citations

Drug Interactions, Marketed Oncology Drugs, Preclinical Drug Evaluation +10

Characterization of Differential Tissue Abundance of Major Non-CYP Enzymes in Human

Abdul Basit, Naveen K. Neradugomma, Christopher C. Wolford et al. · Molecular Pharmaceutics · 2020 · 82 citations

Pathology, Redox Biology, Toxicological Mechanism +23

Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton’s Tyrosine Kinase Inhibitor

Lichuan Liu, Jason Halladay, Young G. Shin et al. · Drug Metabolism and Disposition · 2011 · 73 citations

A Novel Reaction Mediated by Human Aldehyde Oxidase: Amide Hydrolysis of GDC-0834

Jasleen K. Sodhi, Susan Wong, Donald S. Kirkpatrick et al. · Drug Metabolism and Disposition · 2015 · 61 citations · Full text